Coya Therapeutics, Inc.
COYA
NASDAQ·Healthcare·Biotechnology·Mkt cap $111.7M
$4.76
▲ +4.62%
P/E
-4.45
Mkt Cap
$111.7M
52-Wk Range
$3.71–$7.75
52-Week Range
$3.71 - $7.75
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 25.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary Treg-modulation platform with multiple therapeutic modalities
- First-mover advantage in Treg cell therapy for ALS and other neurological diseases
- Diversified pipeline reducing single-program risk
- Established clinical data with COYA 101 Phase 2a completion
Bear Case
1 risk
- Low volatility (beta 0.6).
Growth
Stable outlook
Clinical advancement of COYA 101 toward Phase 2b/pivotal trials for ALS
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Stable
+4.6% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying COYA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 11, 2026
Reported EPS of -$0.28 vs -$0.35 consensus (+19.0% surprise). Revenue of $221.9K vs $130.0K expected (+70.7%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+19.0%
Revenue trend · last 8Q
—
—
+103%
-95%
+4%
—
+97288%
+148874%
Q2 24
Q3 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$3.4M
$0
$257.9K
$163.6K
$3.6M
$4.0M
$251.1M
$243.7M
Margins · last 8Q
Gross
100.0%
Operating
—
Profit
-2723.4%
Wall Street consensus
4 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Roth Capital · Jun 5, 2026
vs Industry
How COYA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related